Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Address

601 Brickell Key Drive

Suite 1000

Website

https://www.smmttx.com

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Mr. Rainer M. Erdtmann

Director

Mr. Robert W. Duggan

Director

Mr. Glyn Owain Edwards MBE

Chairman of the Board/Director

Mr. Manmeet Singh Soni

Director

Ms. Melissa Strange

Secretary

Dr. Elaine Carla Stracker

Director

Dr. Ventzislav Kirilov Stefanov

Director

Ownership

Institution Holdings

BlackRock Inc

9,759,383 (1.391%)

Vanguard Group Inc

7,014,982 (1.000%)

BlackRock Fund Advisors

5,220,027 (0.744%)

Vanguard Investments Australia Ltd

3,691,640 (0.526%)

Fidelity Management & Research Company LLC

3,529,580 (0.503%)

Geode Capital Management, LLC

3,085,666 (0.440%)

State Street Corporation

2,456,168 (0.350%)

Fidelity SelectCo, LLC

2,427,819 (0.346%)

Northern Trust Investments Inc

1,805,883 (0.257%)

State Street Global Advisors

1,373,220 (0.196%)

Funds Holdings

iShares Russell 2000 ETF

2,788,943 (0.397%)

Vanguard Institutional Extnd Mkt Idx Tr

1,833,838 (0.261%)

Fidelity Small Cap Index Fund

1,152,913 (0.164%)

iShares Russell 2000 Growth ETF

1,029,239 (0.147%)

iShares Biotechnology ETF

857,838 (0.122%)

Fidelity Extended Market Index Fund

702,512 (0.100%)

Vanguard Health Care Index Fund

472,278 (0.067%)

State Street Russell Small Cap® Index

449,600 (0.064%)

Vanguard Russell 2000 Index Fund

390,763 (0.056%)

iShares Nasdaq US Biotechnology ETF

363,434 (0.052%)

Details

Overview

Company Info

Key Ratios

Income

Balance Sheet

Cash Flow

Bubble

Make Smart Investment Choices